There is great inconsistency in the classification and management of extensive obstetric perineal injuries. Uniform recommendations should be created and accepted, not only in the Czech and Slovak Republics, but worldwide.
A case of pelvic actinomycosis is presented. The patient is 42-year-old female with a 5 weeks history of pelvic pain. An intrauterine device (IUD) was taken out 3 weeks ago. There is a lump length 9 cm between rectus muscles. Ultrasound, magnetic resonance imaging (MRI) and histology are used to make the diagnosis. Actinomycosis can mimic the tumour disease. The definitive diagnosis requires positive anaerobic culture or histological identification of actinomyces granulas. A long lasting antibiotic therapy is performed.
Poster abstracts USG markers found. Effectiveness was assessed based on 24 cases found due to 1 st trimester calculations. Our 1 st trimester screening sensitivity is 85.71%, false negative results-14.29%, false positive results-2.72%, specificity-98.32%, accuracy-98.19%. Found CA case/invasive procedure ratio is 1/1.3 in fact. In 2 cases (8.3%) from 24 cases of CA we found confined placental mosaicism. Conclusions: 1) Personal risks assessment of CA according to FMF recommendations showed high accuracy; 2) it resulted in significant decreasing of invasive procedures number; 3) to avoid possible diagnostic mistakes because of confined placental mosaicism amniocentesis should be preferred. Objectives: Shifting our strategies of screening from second to first trimester in an OSCAR mannar and make it one of our daily practices. Methods: We present our experience in the University Hospital, Olomouc and the Regional Hospital Zlin. Our decision was based on a one year pilot study at the department and the published data in the field. Pregnant women were booked for in first trimester instead of the second and biochemical screening in the first trimester to substitute the triple test. Anomaly scan was organized for 20-22 weeks of pregnancy including screening of the heart. Minimum investment was made to purchase the software (Astraia) and a blood analyzer (Kryptor). If a women had a screen positive test we immediately progress to CVS and use PCR for the diagnosis, results are available in less than 36 hours. Confirmed pathological cases are terminated according to the wish of the women. Results: We started the clinic in January 2004 in Olomouc and October 2007 in Zlin, we had about 18000 screening, we detected all 51 cases of trisomy 21 (except one) and 67 anther cases of other chromosomal abnormalities for 3.5% false positive rate. Conclusions: Shifting the strategy of prenatal screening required only a minimum investment in terms of money in a large district hospital, with a good use of existing resources including manpower. The new screening method proved a big success with high detection rates, low false positive rates and is very well accepted by women. P17.08 P17.09The frequency of chromosomal abnormalities among fetuses with increased nuchal translucency: an 8 year experience in one cytogenetic clinic Hamchoon Women's Clinic, Seoul, Republic of KoreaObjectives: The purpose of the present study is to determine the frequency of chromosomal abnormalities among singleton fetuses with increased nuchal translucency (NT). Methods: Between January 2002 and December 2009, we performed 1140 procedures for fetal karyotyping, of which indication was increased NT. The cut-off value of increased NT was 3 mm. Of these 1140 procedures, we excluded 210 cases because of multiple pregnancy (n = 199) and failure of cell culture (n = 11). We analyzed remaining 930 cases retrospectively. o., Prague, Czech RepublicObjectives: Czech Republic has one of the highest number of amniocentesis all over Europe (more than 18 000 amniocentesis ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.